| Recruiting | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymp NCT07061951 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Recruiting | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic NCT04941716 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies NCT04892277 | Mayo Clinic | Phase 1 |
| Withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformat NCT04781855 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536 | City of Hope Medical Center | Phase 1 |
| Terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac NCT04659044 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Stu NCT04230304 | Mayo Clinic | Phase 2 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Withdrawn | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324 | Virginia Commonwealth University | Phase 1 |
| Recruiting | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or NCT04169737 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymp NCT03961672 | City of Hope Medical Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom NCT03884972 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non NCT03003546 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL NCT03045328 | Steven E. Coutre | Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Completed | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia NCT02756897 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia o NCT02225275 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02614508 | Emory University | Phase 1 |
| Completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphoc NCT02420912 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Completed | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma NCT01995669 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02160015 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Sm NCT01886859 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |